Javascript must be enabled to continue!
Sub arachnoid hemorrhage and vasospasm
View through CrossRef
Spontaneous sub arachnoid hemorrhage develops vasospasm in the 3-8 days. It should be dealt with conservative symptomatic treatment in this risky phase. Commonest presentation of vasospasm is headache. Usually headache increases with the onset of vasospasm at day 3 and diminishes as the vasospasm subsides after 8-10 days. Surgical interventions like clipping and coiling should be avoided in this period and patients should be given plenty of fluids (hemodilution, hypervolemia and hypertension). This triple H therapy holds good for asymptomatic vasospasms but were found less effective in symptomatic patients of SAH. Constipation should be avoided. Grade is supported by evidence from placebo-controlled study. There are some guidelines available for the prevention and the treatment of cerebral vasospasms with Nimodipine (oral). The use of triple H treatment as a preventative measure is a grade B recommendation. The treatment of symptomatic vasospasm with therapeutic hypertensive hypervolemia hemodilution is advised, however no prospective trials are available (grade C recommendation). There is no evidence that antifibrinolytics, steroids, or anticonvulsive prophylaxis should be used routinely. Current prophylaxis and treatment of cerebral vasospasm are still insufficient, according to clinical data, and vigorous triple-H-therapy is linked to an increased risk of sequelae.
Pakistan Society of Neurosurgeons
Title: Sub arachnoid hemorrhage and vasospasm
Description:
Spontaneous sub arachnoid hemorrhage develops vasospasm in the 3-8 days.
It should be dealt with conservative symptomatic treatment in this risky phase.
Commonest presentation of vasospasm is headache.
Usually headache increases with the onset of vasospasm at day 3 and diminishes as the vasospasm subsides after 8-10 days.
Surgical interventions like clipping and coiling should be avoided in this period and patients should be given plenty of fluids (hemodilution, hypervolemia and hypertension).
This triple H therapy holds good for asymptomatic vasospasms but were found less effective in symptomatic patients of SAH.
Constipation should be avoided.
Grade is supported by evidence from placebo-controlled study.
There are some guidelines available for the prevention and the treatment of cerebral vasospasms with Nimodipine (oral).
The use of triple H treatment as a preventative measure is a grade B recommendation.
The treatment of symptomatic vasospasm with therapeutic hypertensive hypervolemia hemodilution is advised, however no prospective trials are available (grade C recommendation).
There is no evidence that antifibrinolytics, steroids, or anticonvulsive prophylaxis should be used routinely.
Current prophylaxis and treatment of cerebral vasospasm are still insufficient, according to clinical data, and vigorous triple-H-therapy is linked to an increased risk of sequelae.
Related Results
Effect of Parenchymal Arachnoid on Brain Fluid Transport
Effect of Parenchymal Arachnoid on Brain Fluid Transport
Introduction: The pia-arachnoid is a critical component of cerebrospinal fluid removal. It covers and invaginates into the brain parenchyma, and physiologic failure results in hydr...
Milrinone for refractory cerebral vasospasm with delayed cerebral ischemia
Milrinone for refractory cerebral vasospasm with delayed cerebral ischemia
OBJECTIVEIntravenous (IV) milrinone is a promising option for the treatment of cerebral vasospasm with delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (aSA...
Therapeutic approaches to cerebral vasospasm complicating ruptured aneurysm
Therapeutic approaches to cerebral vasospasm complicating ruptured aneurysm
Cerebral vasospasm is a serious complication of ruptured aneurysm. In order to avoid short- and long-term effects of cerebral vasospasm, and as there is no single or optimal treatm...
Real-world data of clazosentan for aneurysmal subarachnoid hemorrhage: a multicenter retrospective cohort study
Real-world data of clazosentan for aneurysmal subarachnoid hemorrhage: a multicenter retrospective cohort study
Abstract
Aneurysmal subarachnoid hemorrhage (aSAH) may lead to cerebral vasospasm which is significantly associated with morbidity and mortality. Clazosentan, an endothelin...
Vasospasm in Cerebral Inflammation
Vasospasm in Cerebral Inflammation
All forms of cerebral inflammation as found in bacterial meningitis, cerebral malaria, brain injury, and subarachnoid haemorrhage have been associated with vasospasm of cerebral ar...
Contribution of Src tyrosine kinase to cerebral vasospasm after subarachnoid hemorrhage
Contribution of Src tyrosine kinase to cerebral vasospasm after subarachnoid hemorrhage
Object. Mitogen-activated protein kinase (MAPK) has been implicated in cerebral vasospasm after subarachnoid hemorrhage (SAH). This study was conducted to investigate whether Src t...
Experimental Study of Cerebral Vasospasm Induced by Serotonin and Oxyhemoglobin in Subarachnoid Hemorrhage
Experimental Study of Cerebral Vasospasm Induced by Serotonin and Oxyhemoglobin in Subarachnoid Hemorrhage
To clarify the mechanism of cerebral vasospasm induced by serotonin (5-HT) and oxyhemoglobin (OxyHb), the authors studied the roles of vasoactive pros taglandins (PGs) and free rad...
Review/Perspective On the Diagnosis and Surgical Management of Spinal Arachnoid Cysts
Review/Perspective On the Diagnosis and Surgical Management of Spinal Arachnoid Cysts
Background:
Spinal arachnoid cysts (SAC) are typically congenital, spontaneous, traumatic (i.e., including iatrogenic/surgical), or inflammatory in origin. In descending order, th...

